Reports Q2 revenue $1.36M, consensus $80,000. “During the second quarter, we continued to advance our oral pill vaccine programs and deliver on our planned timelines for this year,” said Andrei Floroiu, Vaxart’s CEO. “Positive preliminary topline data from our Phase 2 bivalent norovirus vaccine candidate builds on the growing body of evidence supporting Vaxart’s platform and the potential advantages of mucosal vaccination.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VXRT:
- Vaxart Provides Business Update and Reports Second Quarter 2023 Financial Results
- Vaxart reports positive topline Phase 2 data of norovirus vaccine candidate
- Vaxart Stockholders Approve All Four Proposals in the 2023 Proxy Statement
- Vaxart Encourages All Stockholders of Record as of April 28, 2023 to Vote by June 25, 2023, at 11:59 p.m. ET
- Vaxart, Inc. Announces Pricing of $15,000,000 Public Offering of Common Stock
